Post: Scientific Officer
[adsense:336x280:8701650588]
No.of post: 10
Taro Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Keveyis™ (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.[1] Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.[2]
Researchers have discovered a way to trigger a preventive response to a flu infection without any help from the usual players – the virus itself or interferon, a powerful infection fighter.
People with type 1 diabetes who use insulin pump therapy face almost 50% less risk of dying from cardiovascular disease than those who take insulin by multiple daily injections. The British Medical Journal has published a study conducted at Sahlgrenska Academy.
A new smartphone app that monitors patients suffering from chronic cardiopulmonary diseases by analysing the way they walk can warn doctors at the first sign of trouble. Using the health-tracking app, MoveSense, developed by researchers at the University of Illinois at Urbana-Champaign, a patient's oxygen saturation level can be passively monitored with medical accuracy. Oxygen saturation is a standard measure of health status.